Christopher Thomas Giordano - 10 Dec 2024 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
CEO, Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
10 Dec 2024
Net transactions value
$0
Form type
4
Filing time
12 Dec 2024, 20:02:03 UTC
Previous filing
21 May 2024
Next filing
20 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +1,250,000 $0.000000 1,250,000 10 Dec 2024 Common Stock 1,250,000 $5.94 Direct
holding TENX Stock Option (right to buy) 157 10 Dec 2024 Common Stock 157 $3152.00 Direct F1
holding TENX Stock Option (right to buy) 125 10 Dec 2024 Common Stock 125 $992.00 Direct F2
holding TENX Stock Option (right to buy) 437 10 Dec 2024 Common Stock 437 $3.55 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F2 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F3 The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.